H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers

Acta Neuropathologica

Volumn 134, Issue 3, 2017, Pages 507-516

  Korshunov, Andrey ^a,b   Schrimpf, Daniel ^a,b   Ryzhova, Marina ^c   Sturm, Dominik ^a,b   Chavez, Lukas ^a   Hovestadt, Volker ^a   Sharma, Tanvi ^a   Habel, Antje ^a,b   Burford, Anna ^d   Jones, Chris ^d   Zheludkova, Olga ^e   Kumirova, Ella ^f   Kramm, Christof M ^g   Golanov, Andrey ^c   Capper, David ^a,b   von Deimling, Andreas ^a,b   Pfister, Stefan M ^a,b   Jones, David T W ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e Chemistry Moscow Russia   (Russian Federation)

^f Oncology   (Russian Federation)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Brain tumor; EGFR; Glioblastoma; Methylation; MYCN; PDGFRA; Pediatric; Prognostic; RTK; Subgroup; Survival

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; H3F3A PROTEIN; HIST1H3A PROTEIN; HIST1H3B PROTEIN; HIST1H3C PROTEIN; HIST2H3C PROTEIN; HISTONE H3; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MYCN PROTEIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; UNCLASSIFIED DRUG; HISTONE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENOME ANALYSIS; GENOME-WIDE ASSOCIATION STUDY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PEDIATRICS; PRIORITY JOURNAL; SURVIVAL TIME; WILD TYPE; BRAIN TUMOR; CARCINOGENESIS; DNA MUTATIONAL ANALYSIS; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROMOTER REGION;

ADOLESCENT; BRAIN NEOPLASMS; CARCINOGENESIS; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GLIOBLASTOMA; HISTONES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MUTATION; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 85017450635     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-017-1710-1     Document Type: Article

References (34)

1. Arrondeau J, Huillard O, Tlemsani C, Cessot A, Boudou-Rouquette P, Blanchet B, Thomas-Schoemann A, Vidal M, Tigaud JM, Durand JP et al (2015) Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. Expert Opin Investig Drugs 24:673–687. doi:10.1517/13543784.2015.1005736
2. Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL et al (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547–560. doi:10.1007/s00401-012-1016-2
3. Bender S, Gronych J, Warnatz HJ, Hutter B, Groebner S, Ryzhova M, Pfaff E, Hovestadt V, Weinberg F, Halbach S et al (2016) Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med 22:1314–1320. doi:10.1038/nm.4204
4. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U et al (2014) Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46:451–456. doi:10.1038/ng.2936
5. Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N, Pages M, Taylor KR, Saulnier P, Lacroix L et al (2015) Histone H3F3A and HIST1H3B K27 M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol 130:815–827. doi:10.1007/s00401-015-1478-0
6. Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS et al (2011) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol 13:317–323. doi:10.1093/neuonc/noq191
7. Duffner PK, Horowitz ME, Krischer JP, Burger PC, Cohen ME, Sanford RA, Friedman HS, Kun LE (1999) The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol 1:152–161
8. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA et al (2014) Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 46:462–466. doi:10.1038/ng.2950
9. Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R, Cavalli FM, Ramaswamy V, Zapatka M, Reifenberger G et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125:913–916. doi:10.1007/s00401-013-1126-5
10. Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer. doi:10.1038/nrc3811
11. Jones C, Perryman L, Hargrave D (2012) Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol 9:400–413. doi:10.1038/nrclinonc.2012.87
12. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L et al (2012) K27 M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124:439–447. doi:10.1007/s00401-012-0998-0
13. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026. doi:10.1073/pnas.1303607110
14. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Bohmer K et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–915. doi:10.1007/s00401-013-1195-5
15. Korshunov A, Capper D, Reuss D, Schrimpf D, Ryzhova M, Hovestadt V, Sturm D, Meyer J, Jones C, Zheludkova O et al (2016) Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131:137–146. doi:10.1007/s00401-015-1493-1
16. Korshunov A, Ryzhova M, Hovestadt V, Bender S, Sturm D, Capper D, Meyer J, Schrimpf D, Kool M, Northcott PA et al (2015) Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129:669–678. doi:10.1007/s00401-015-1405-4
17. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, Von Deimling A (2016) WHO classification of tumours of the central nervous system, revised, 4th edn. IARC, City
18. Northcott PA, Pfister SM, Jones DT (2015) Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. Lancet Oncol 16:e293–e302. doi:10.1016/S1470-2045(14)71206-9
19. Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Finlay JL, Stearns DS, Wolff JE, Wolinsky Y, Letterio JJ et al (2015) Alex’s Lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 10):x1–x36. doi:10.1093/neuonc/nou327
20. Pajtler KW, Witt H, Sill M, Jones DT, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728–743. doi:10.1016/j.ccell.2015.04.002
21. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D et al (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061–3068. doi:10.1200/JCO.2009.26.7252
22. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G et al (2013) PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol 23:565–573. doi:10.1111/bpa.12043
23. Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, Andreiuolo F, Carvalho D, Reis R, Guerrini-Rousseau L et al (2012) Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One 7:e30313. doi:10.1371/journal.pone.0030313
24. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P et al (2013) Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 3:308–323. doi:10.1158/2159-8290.CD-12-0418
25. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146. doi:10.1007/s00401-014-1370-3
26. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231. doi:10.1038/nature10833
27. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF et al (2014) Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14:92–107. doi:10.1038/nrc3655
28. Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I et al (2016) New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164:1060–1072. doi:10.1016/j.cell.2016.01.015
29. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437. doi:10.1016/j.ccr.2012.08.024
30. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, Castel D, Grasso CS, Vinci M, Carvalho D et al (2014) Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46:457–461. doi:10.1038/ng.2925
31. van der Maarten L, Hinton G (2008) Visualizing high-dimensional data using t-SNE. J Mach Learn Res 9:2579–2605
32. Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, Boudalil M, Previti C, Wolf S, Schmidt S et al (2016) Next-generation personalised medicine for high-risk paediatric cancer patients—the INFORM pilot study. Eur J Cancer 65:91–101. doi:10.1016/j.ejca.2016.06.009
33. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, Qu C, Ding L, Huether R, Parker M et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44:251–253. doi:10.1038/ng.1102
34. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, Zhu X, Qu C, Chen X, Zhang J et al (2014) The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46:444–450. doi:10.1038/ng.2938